Consideration of the ischaemic basis and treatment of Alzheimer's disease: Dedicated in Honor of my Mother Antonina Pluta (1922-2009) and Assistant Professor Irmina Zelman my Mentor and Friend (1927-2010)

Folia Neuropathologica

Volumn 48, Issue 1, 2010, Pages 11-26

  Pluta, Ryszard ^a   Ułamek, Marzena ^a   Jabłoński, Mirosław ^b  

^a POLISH ACADEMY OF SCIENCES   (Poland)

^b MEDICAL UNIVERSITY OF LUBLIN   (Poland)

Author keywords

Alzheimer's disease; Amyloid therapy; Blood brain barrier therapy; Gene therapy; Immunotherapy; Inflammation therapy; Ischaemic etiology; Tau protein therapy

Indexed keywords

AMYLOID; AMYLOID BETA PROTEIN; AUTOANTIBODY; BETA SECRETASE; CALCIUM; CANNABINOID; CURCUMIN; DIPEPTIDYL CARBOXYPEPTIDASE; ENDOTHELIN CONVERTING ENZYME; ENOXAPARIN; GELSOLIN; HEAT SHOCK PROTEIN; IMMUNOGLOBULIN; INSULINASE; LIPID; MEGALIN; MEMANTINE; MEMBRANE METALLOENDOPEPTIDASE; PEPTIDE VACCINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; STATIN; TAU PROTEIN; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ALZHEIMER DISEASE; BLOOD BRAIN BARRIER; BRAIN HEMORRHAGE; BRAIN HYPOXIA; BRAIN ISCHEMIA; CALCIUM BLOOD LEVEL; CLINICAL TRIAL; CORD BLOOD STEM CELL TRANSPLANTATION; DISEASE ASSOCIATION; DISEASE COURSE; DOWN REGULATION; DRUG EFFECT; EXPERIMENTAL MODEL; EXPERIMENTAL THERAPY; GENE EXPRESSION; GENE THERAPY; GENE TRANSFER; HOMEOSTASIS; HUMAN; IMMUNOMODULATION; IMMUNOTHERAPY; IN VIVO STUDY; INFLAMMATION; LIPID BLOOD LEVEL; MENINGOENCEPHALITIS; NERVE CELL NECROSIS; NERVE DEGENERATION; NEUROFIBRILLARY TANGLE; NEUROPATHOLOGY; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PROTEIN TRANSPORT; REVIEW; RISK ASSESSMENT; SENILE PLAQUE; SIGNAL TRANSDUCTION; UMBILICAL CORD BLOOD; VACCINATION;

EID: 77950808419     PISSN: 16414640     EISSN: 1509572X     Source Type: Journal    
DOI: None     Document Type: Review

References (193)

1. Alonzo NC, Hyman BT, Rebeck GW, Greenberg SM. Progression of cerebral amyloid angiopathy: accumulation of amyloid-beta 40 in affected vessels. J Neuropathol Exp Neurol 1998; 57: 353- 359.
2. Alvarez XA, Cacabelos R, Laredo M, Couceiro V, Sampedro C, Varela M, Corzo L, Fernandez-Novoa L, Vargas M, Aleixandre M, Linares C, Granizo E, Muresanu D, Moessler H. A 24-week, double-blind, placebo-controlled study of three dosages of Cerebrolysin in patients with mild to moderate Alzheimer's disease. Eur J Neurol 2006; 13: 43-54.
3. Alzheimer A. Über eine eigenartige Erkrankung der Hirnrinde. Allg Z Psychiatr Psych Gericht Med (Berlin) 1907; 64: 146-148.
4. Anfuso CD, Assero G, Lupo G, Nicota A, Cannavo G, Strosznajder RP, Rapisarda P, Pluta R, Alberghina M. Amyloid beta (1-42) and its beta (25-35) fragment induce activation and membrane translocation of cytosolic phospholipase A(2) in bovine retina capillary pericytes. Biochim Biophys Acta 2004; 1686: 125-138. (Pubitemid 39446885)
5. Armstrong RA. Spatial correlation between β-amyloid (Aβ) deposits and blood vessels in familial Alzheimer's disease. Folia Neuropathol 2008; 46: 241-248.
6. Armstrong RA. The molecular biology of senile plaques and neurofibrillary tangles in Alzheimer's disease. Folia Neuropathol 2009; 47: 289-299.
7. Ashe KH. Learning and memory in transgenic mice modeling Alzheimer's disease. Learn Mem 2001; 8: 301-308. (Pubitemid 34037573)
8. Badin RA, Lythgoe MF, Van der Weerd L, Thomas DL, Gadian DG, Latchman DS. Neuroprotective effects of virally delivered HSPs in experimental stroke. J Cereb Blood Flow Metab 2006; 26: 371-381. (Pubitemid 43297918)
9. Bailey TL, Rivara CB, Rocher AB, Hof PR. The nature and effects of cortical microvascular pathology in aging and Alzheimer's disease. Neurol Res 2004; 26: 573-578. (Pubitemid 38879242)
10. Bard F, Cannon C, Barbour R, Burke RL, Games D, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Lieberburg I, Motter R, Nguyen M, Soriano F, Vasquez N, Weiss K, Welch B, Seubert P, Schenk D, Yednock. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 2000; 6: 916-919. (Pubitemid 30644751)
11. Barone FC, Arvin B, White RF, Miller A, Webb CL, Willette RN, Lysko PG, Feuerstein GZ. Tumor necrosis factor-alpha. A mediator of focal ischemic brain injury. Stroke 1997; 28: 1233-1244. (Pubitemid 27248902)
12. Bell RD, Deane R, Chow N, Long X, Sagare A, Singh I, Streb JW, Guo H, Rubio A, Van Nostrand W, Miano JM, Zlokovic BV. SRF and myocardin regulate LRP-mediated amyloid-beta clearance in brain vascular cells. Nat Cell Biol 2009; 11: 143-153.
13. Bell RD, Zlokovic BV. Neurovascular mechanisms and bloodbrain barrier disorder in Alzheimer's disease. Acta Neuropathol 2009;118: 103-113.
14. Benarroch E. Neurovascular unit dysfunction: A vascular component of Alzheimer disease? Neurology 2007; 68: 1730-1732.
15. Bennett DA, Wilson RS, Schneider JA, Evans DA, Mendes de Leon CF, Arnold SE, Barness LL, Bienias JL. Education modifies the relation of AD pathology to level of cognitive function in older persons. Neurology 2003; 60: 1909-1915. (Pubitemid 36736005)
16. Bergamaschini L, Rossi E, Storini C, Pizzimenti S, Distaso M, Pergo C, De Luigi A, Vergani C, De Simoni MG. Peripheral treatment with enoxaparin, a low molecular weight heparin, reduces plaques and beta-amyloid accumulation in a mouse model of Alzheimer's disease J Neurosci 2004; 24: 4181-4186. (Pubitemid 38620793)
17. Best JD, Jay MT, Out F, Churcher I, Reilly M, Morentin-Gutierrez P, Pattison C, Harrison T, Shearman MS, Atack JR. In vivo characterization of Aβ(40) changes in brain and cerebrospinal fluid using the novel γ-secretase inhibitor N-[cis-4-[(4- chlorophenyl)sulfonyl]-4-(2, 5-difluorophenyl)cyclohexyl]-1, 1, 1- trifluoromethane-sulfonamide (MRK-560) in the rat. J Pharmacol Exp Ther 2006; 317: 786-790.
18. Blanchard BJ, Chen A, Rozenboom LM, Stafford KA, Weigele P, Ingram VM. Efficient reversal of Alzheimer's disease fibril formation and elimination of neurotoxicity by a small molecule. Proc Natl Acad Sci USA 2004; 101: 14326-14332. (Pubitemid 39346748)
19. Blennow K, Wallin A, Fredman P, Karlsson I, Gottfries CG, Svennerholm L. Blood-brain barrier disturbance in patients with Alzheimer's disease is related to vascular factors. Acta Neurol Scand 1990; 81: 323-326. (Pubitemid 20174132)
20. Borlongan CV, Lind JG, Dillon-Carter O, Yu G, Hadman M, Cheng C, Carroll J, Hess DC. Bone marrow grafts restore cerebral blood flow and blood-brain barrier in stroke rats. Brain Res 2004; 1010: 108-116. (Pubitemid 38569858)
21. Boutin H, LeFeuvre RA, Horai R, Asano M, Iwakura Y, Rothwell NJ. Role of IL-1alpha and IL-1beta in ischemic brain damage. J Neurosci 2001; 21: 5528-5534. (Pubitemid 32692151)
22. Bowman GL, Kaye JA, Moore M, Waichunas D, Carlson NE, Quinn JF. Blood-brain barrier impairment in Alzheimer disease: stability and functional significance. Neurology 2007; 68: 1809-1814. (Pubitemid 46791393)
23. Cao YJ, Shibata T, Rainov NG. Liposome-mediated transfer of the bcl-2 gene results in neuroprotection after in vivo transient focal cerebral ischemia in an animal model. Gene Ther 2002; 9: 415-419. (Pubitemid 34414040)
24. Cheng T, Liu D, Griffin JH, Fernandez JA, Castellio F, Rosen ED, Fukudome K, Zlokovic BV. Activated protein C blocks p53- mediated apoptosis in ischemic human brain endothelium and is neuroprotective. Nat Med 2003; 9: 338-342. (Pubitemid 36362790)
25. Chirita C, Necula M, Kuret J. Ligand-dependent inhibition and reversal of tau filament formation. Biochemistry 2004; 43: 2879-2887. (Pubitemid 38327819)
26. Chohan MO, Khatoon S, Grundke-Iqbal IG, Iqbal K. Involvement of I2PP2A in the abnormal hyperphosphorylation of tau and its reversal by memantine. FEBS Lett 2006; 580: 3973- 3979. (Pubitemid 43946883)
27. Christensen DD. Changing the course of Alzheimer's disease: Anti-amyloid disease-modifying treatments on the horizon. Prim Care Companion J Clin Psychiatry 2007; 9: 32-41. (Pubitemid 46280276)
28. Clark WM, Madden KP, Rothlein R, Zivin J. Reduction of central nervous system ischemic injury in rabbits using leukocyte adhesion antibody treatment. Stroke 1991; 22: 877-883.
29. Clark CM, Xie S, Chittams J, Ewbank D, Peskind E, Galasko D, Morris JC, McKeel DWJr, Farlow M, Weitlauf SL, Quinn J, Kaye J, Knopman D, Arai H, Doody RS, DeCarli C, Leight S, Lee VH, Trojanowski JQ. Cerebrospinal fluid tau and β-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses? Arch Neurol 2003; 60: 1696-1702. (Pubitemid 37521622)
30. Corrada MM, Head E, Kim R, Kawas C. Braak and Braak staging and dementia in the oldest-old: preliminary results from the 90+ study. Neurology 2005; 64: A276.
31. Cullen KM, Kocsi Z, Stone J. Pericapillary haem-rich deposits evidence for microhaemorrhages in aging human cerebral cortex. J Cereb Blood Flow Metab 2005; 25: 1656-1667. (Pubitemid 41683176)
32. Davis DG, Schmidt FA, Wekstein DR, Markesbery WR. Alzheimer neuropathologic alterations in aged cognitively normal subjects. J Neuropathol Exp Neurol 1999; 58: 376-388.
33. Deane R, Du Yan S, Submamaryan RK, LaRue B, Jovanovic S, Hogg E, Welch D, Manness L, Lin C, Yu J, Zhu H, Ghiso J, Frangione B, Stern A, Schmidt AM, Armstrong DL, Arnold B, Liliensiek B, Nawroth P, Hofman F, Kindy M, Stern D, Zlokovic BV. RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain. Nat Med 2003; 9: 907-913. (Pubitemid 36889934)
34. Deane R, Wu Z, Sagare A, Davis J, Du Yan S, Hamm K, Xu F, Parisi M, LaRue B, Hu HW, Spijkers P, Guo H, Song X, Lenting PJ, Van Nostrand WE, Zlokovic BV. LRP/amyloid beta-peptide interaction mediates differential brain efflux of Abeta isoforms. Neuron 2004; 43: 333-344. (Pubitemid 39061126)
35. Deane R, Wu Z, Zlokovic BV. RAGE (yin) versus LRP (yang) ba lance regulates alzheimer amyloid beta-peptide clearance through transport across the blood-brain barrier. Stroke 2004; 35 (11 Suppl 1): 2628-2631. (Pubitemid 39458354)
36. Deane R, Sagare A, Hamm K, Parisi M, LaRue B, Guo H, Wu Z, Holtzman DM, Zlokovic BV. IgG-assisted age-dependent clearance of Alzheimer's amyloid beta peptide by the blood-brain barrier neonatal Fc receptor. J Neurosci 2005; 25: 11495-11503. (Pubitemid 43102486)
37. De Felice FG, Vieira MN, Saraiva LM, Figueroa-Villar JD, Garcia- Abreu J, Liu R, Chang L, Klein WL, Ferreira ST. Targeting the neurotoxic species in Alzheimer's disease: inhibitors of Abeta oligomerization. FASEB J 2004; 18: 1366-1372. (Pubitemid 39150351)
38. De la Torre JC. Vascular basis of Alzheimer's pathogenesis. Ann NY Acad Sci 2002; 977: 196-215.
39. De la Torre JC. Alzheimer's disease is a vasocognopathy: a new term to describe its nature. Neuronal Res 2004; 26: 517-524.
40. De la Torre JC. Is Alzheimer's disease preceded by neurodegeneration or cerebral hypoperfusion? Ann Neurol 2005; 57: 783-784. (Pubitemid 40798614)
41. DeMattos RB, Bales KR, Cummins DJ, Dodart JC, Paul SM, Holtzman DM. Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decrease brain A beta burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 2001; 98: 8850-8855.
42. DeMattos RB, Bales KR, Cummins DJ, Paul SM, Holtzman DM. Brain to plasma amyloid- efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease. Science 2002; 295: 2264-2267. (Pubitemid 34258840)
43. Dickstein DL, Biron KE, Ujiie M, Pfeifer CG, Jeffries AR, Jefferies WA. Abeta peptide immunization restores blood-brain barrier integrity in Alzheimer disease. FASEB J 2006; 20: 426-433. (Pubitemid 44933319)
44. Dodel RC, Du Y, Depboylu C, Hampel H, Frolich L, Haag A, Hemmeter U, Paulsen S, Teipel SJ, Brettschneider S, Spottke A, Nolker C, Moller HJ, Wie X, Farlow M, Sommer N, Oertel WH. Intravenous immunoglobulins containing antibodies against beta-amyloid for the treatment of Alzheimer's disease. J Neurol Neurosurg Psychiatry 2004; 75: 1472-1474. (Pubitemid 39279821)
45. Dovey HF, John V, Anderson JP, Chen LZ, de Saint Andrieu P, Fang LY, Freedman SB, Folmer B, Goldbach E, Holsztynska EJ, Hu KL, Johnson-Wood KL, Kennedy SL, Kholodenko D, Knops JE, Latimer LH, Lee M, Liao Z, Lieberburg IM, Motter RN, Mutter LC, Nietz J, Quinn KP, Sacchi KL, Seubert PA, Shopp GM, Thorsett ED, Tung JS, Wu J, Yang S, Yin CT, Schenk DB, May PC, Altstiel LD, Bender MH, Boggs LN, Britton TC, Clemens JC, Czilli DL, Dieckman-McGinty DK, Droste JJ, Fuson KS, Gitter BD, Hyslop PA, Johnstone EM, Li WY, Little SP, Mabry TE, Miller FD, Audia JE. Functional gamma-secretase inhibitors reduce betaamyloid peptide levels in the brain. J Neurochem 2001; 76: 173- 181. (Pubitemid 32044380)
46. Echeverria V, Clerman A, Dore S. Stimulation of PGE2 receptors EP2 and EP4 protects cultured neurons against oxidative stress and cell death following beta-amyloid exposure. Eur J Neurosci 2005; 22: 2199-2206. (Pubitemid 41653533)
47. Eckman EA, Watson M, Marlow L, Sambamurti K, Eckman CB. Alzheimer's disease beta-amyloid peptide is increased in mice deficient in endothelin-converting enzyme. J Biol Chem 2003; 278: 2081-2084. (Pubitemid 36801269)
48. Eckman EA, Eckman CB. Abeta-degrading enzymes: modulators of Alzheimer's disease pathogenesis and targets for therapeutic intervention. Biochem Soc Trans 2005; 33: 1101-1105.
49. El Mouedden M, Vandermeeren M, Meet T, Mercken M. Reduction of Abeta levels in the Sprague Dawley rat after oral administration of the functional gamma-secretase inhibitor, DAPT: a novel non-transgenic model for Abeta production inhibitors. Curr Pharm Des 2006; 12: 671-676.
50. Etiene D, Kraft J, Ganju N, Gomez-Isla T, Gemelli B, Hyman BT, Hedley-Whyte ET, Wands JR, De La Monte SM. Cerebrovascular pathology contributes to the heterogeneity of Alzheimer's disease. J Alzheimers Dis 1998; 1: 119-134.
51. Farkas IG, Czigner A, Farkas E, Dobo E, Soos K, Penke B, Endresz V, Mihaly A. Beta-amyloid peptide-induced blood-brain barrier disruption facilitates T-cell entry into the rat brain. Acta Histochem 2003; 1005: 115-125. (Pubitemid 36734149)
52. Fiala M, Zhang L, Gan X, Sherry B, Taub D, Graves MC, Hama S, Way D, Weinand M, Witte M, Lorton D, Kuo YM, Roher AE. Amyloid-beta induces chemokine secretion and monocyte migration across a human blood-brain barrier model. Mol Med 1998; 4: 480-489. (Pubitemid 28419092)
53. Fillit HM, Doody Smith R, Binaso KB, Crooks GM, Ferris SH, Farlow MR, Leifer B, Mills Ch, Minkoff N, Orland B, Reichman WE, Salloway S. Recommendations for best practices in the treatment of Alzheimer's disease in managed care. Am J Geriatr Pharmacother 2006; 4 Suppl A: S9-S24. (Pubitemid 44848197)
54. Gilman S, Koller M, Black RS, Jenkins L, Griffith SG, Fox NC, Eisner L, Kirby L, Rovira MB, Forette F, Orgogozo JM, AN1792 (QS- 21)-201 Study Team. Clinical effects of Abeta immunization (AN1792) in patients with Alzheimer's disease in an interrupted trial. Neurology 2005; 64: 1553-1562. (Pubitemid 40617691)
55. Glenner GG, Wong CW. Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun 1984; 120: 885-890. (Pubitemid 14104991)
56. Gong CX, Singh TJ, Grundke-Iqbal I, Iqbal K. Phosphoprotein phosphatase activities in Alzheimer disease. J Neurochem 1993; 61: 921-927. (Pubitemid 23241228)
57. Gong Y, Chang L, Viola KL, Loacor PN, Lambert MP, Finch CE, Krafft GA, Klein WL. Alzheimer's disease-affected brain: presence of oligomeric A beta ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proc Natl Acad Sci USA 2003; 100: 10417-10422. (Pubitemid 37071893)
58. Grammas P, Ovase R. Inflammatory factors are elevated in brain microvessels in Alzheimer's disease. Neurobiol Aging 2001; 22: 837-842. (Pubitemid 34066550)
59. Gunnarsson MD, Kilander L, Sudelof J, Basun H, Lannfelt L. Reduction of hyperphosphorylated tau during memantine treatment of Alzheimer's disease. Alzheimer's & Dementia Suppl. 2006; 2: S63-S64.
60. Guo H, Liu D, Gelbard H, Cheng T, Insalaco R, Fernandez JA, Griffin JH, Zlokovic BV. Activated protein C prevents neuronal apoptosis via protease-activated receptors 1 and 3. Neuron 2004; 41: 563-572. (Pubitemid 38253068)
61. Haroutunian V, Perl DP, Dushyant P, Purohit DP, Marin D, Khan K, Lantz M, Davis KL, Mohs RC. Regional distribution of neurotic plaques in the nondemented elderly and subjects with very mild Alzheimer's disease. Arch Neurol 1998; 55: 1185-1191. (Pubitemid 28427489)
62. Hawkes ChA, McLaurin J. Immunotherapy as treatment for Alzheimer's disease. Expert Rev Neurotherapeutics 2007; 7: 1535-1548. (Pubitemid 350106833)
63. Hemming ML, Selkoe DJ. Amyloid beta-protein is degraded by cellular angiotensin-converting enzyme (ACE) and elevated by an ACE inhibitor. J Biol Chem 2005; 280: 37644-37650.
64. Hemming ML, Patterson M, Reske-Nielsen C, Lin L, Isacson O, Selkoe DJ. Reducing amyloid plaque burden via ex vivo gene delivery of an Abeta-degrading protease: a novel therapeutic approach to Alzheimer disease. PLoS Med 2007; 4: 1405-1416. (Pubitemid 47358176)
65. Heneka MT, Sastre M, Dumitrescu-Ozimek L, Hanke A, Dewachter I, Kuiperi C, O'Banion K, Klockgether T, Van Leuven F, Landreth GE. Acute treatment with the PPARγ agonist piogli-tazone and ibuprofen reduces glial inflammation and Aβ1-42 levels in APPV7171 transgenic mice. Brain 2005; 128: 1442- 1453. (Pubitemid 40826196)
66. Herz J. LRP: a bright beacon at the blood-brain barrier. J Clin Invest 2003; 112: 1483-1485.
67. Higgins GA, Jacobsen H. Transgenic mouse models of Alzheimer's disease: phenotype and application. Behav Pharmacol 2003; 14: 419-438. (Pubitemid 37176800)
68. Humpel C, Marksteiner J. Cerebrovascular damage as a cause for Alzheimer's disease. Curr Neurovasc Res 2005; 2: 341-347. (Pubitemid 41297371)
69. Iadecola C. Neurovascular regulation in the normal brain and in Alzheimer's disease. Nat Rev Neurosci 2004; 5: 347-360. (Pubitemid 38568496)
70. Iqbal K, Grudke-Iqbal I. Inhibition of neurofibrillary degeneration: a promising approach to Alzheimer's disease and other tauopathies. Curr Drug Targets 2004; 5: 495-502. (Pubitemid 39004424)
71. Iqbal K, Flory M, Khatoon S, Soininen H, Pirttila T, Lehtovirta M, Alafuzoff I, Blennow K, Andreasen N, Vanmechelen E, Grundke- Iqbal I. Subgroups of Alzheimer's disease based on cerebrospinal fluid molecular markers. Ann Neurol 2005; 58: 748- 757. (Pubitemid 41552550)
72. Iqbal K, Grundke-Iqbal I. Metabolic/signal transduction hypothesis of Alzheimer's disease and other tauopathies. Acta Neuropathol 2005; 109: 25-31. (Pubitemid 40287787)
73. Iwata N, Tsubuki S, Takaki Y, Shirotani K, Lu B, Gerard NP, Gerard C, Hama E, Lee HJ, Saido TC. Metabolic regulation of brain Abeta by neprilysin. Science 2001; 292: 1550-1552. (Pubitemid 32493424)
74. Jendroska K, Hoffmann OM, Patt S. Amyloid beta peptide and precursor protein (APP) in mild and severe brain ischemia. Ann NY Acad Sci 1997; 826: 401-404. (Pubitemid 27478062)
75. Kalaria RN, Ballard C. Overlap between pathology of Alzheimer's disease and vascular dementia. Alzheimer Dis Assoc Disord 1999; 13: S115-S123.
76. Kalaria RN. The role of cerebral ischemia in Alzheimer's di sease. Neurobiol Aging 2000; 21: 321-330.
77. Kalaria RN. Small vessel disease and Alzheimer's dementia: Pathological considerations. Crebrovasc Dis 2002; 13 Suppl 2: 48-52. (Pubitemid 34233909)
78. Kalback W, Esh C, Castano EM, Rahman A, Kokjohn T, Luehrs DC, Sue L, Cisneros R, Gerber F, Richardson C, Bohrmann B, Walker DG, Beach TG, Roher AE. Atherosclerosis, vascular amyloidosis and brain hypoperfusion in the pathogenesis of sporadic Alzheimer's disease. Neurol Res 2004; 26: 525-539. (Pubitemid 38879235)
79. Kanemitsu H, Tomiyama T, Mori H. Human neprilysin is capable of degrading amyloid beta peptide not only in the monomeric form but also the pathological oligomeric form. Neurosci Lett 2003; 350: 113-116. (Pubitemid 37101425)
80. Kawai M, Kalaria RN, Harik SI, Perry G. The relationship of amyloid plaques to cerebral capillaries in Alzheimer's disease. Am J Pathol 1990; 137: 1435-1446.
81. Katzman R, Terry R, DeTeresa R, Brown T, Davies P, Fuld P, Renbing X, Peck A. Clinical, pathological and neurochemical changes in dementia: a subgroup with preserved mental status and numerous neocortical plaques. Ann Neurol 1988; 23: 138-144. (Pubitemid 18081451)
82. Kim HD, Jin JJ, Maxwell A, Fukuchi K. Enhancing Th2 immune responses against amyloid protein by a DNA prime-adenovirus boost regimen for Alzheimer's disease. Immunol Lett 2007; 112: 30-38. (Pubitemid 47331686)
83. Klafki HW, Staufenbiel M, Kornhuber J, Wiltfang J. Therapeutic approaches to Alzheimer's disease. Brain 2006; 129: 2840- 2855. (Pubitemid 44684507)
84. Koistinaho M, Kettunen MI, Goldsteins G, Keinanen R, Salminen A, Ort M, Bures J, Liu D, Kauppinen RA, Higgins LS, Koistinaho J. Beta-amyloid precursor protein transgenic mice that harbor diffuse A beta deposits but do not form plaques show increased ischemic vulnerability: role of inflammation. Proc Natl Acad Sci USA 2002; 99: 1610-1615. (Pubitemid 34136540)
85. Koistinaho M, Lin S, Wu X, Esterman M, Koger D, Hanson J, Higgs R, Liu F, Malkani S, Bales KR, Paul SM. Apolipoprotein E promotes astrocyte colocalization and degradation of deposited amyloid-beta peptides. Nat Med 2004; 10: 719-726. (Pubitemid 38937637)
86. Kudo T, Imaizumi K, Tanimukai H, Katayama T, Sato N, Nakamura Y, Tanaka T, Kashiwagi Y, Jinno Y, Tohyama M, Takeda M. Are cerebrovascular factors involved in Alzheimer's disease? Neurobiol Aging 2000; 21: 215-224. (Pubitemid 30387080)
87. Lam FC, Liu R, Lu P, Shapiro AB, Renoir JM, Sharoni FJ, Reiner PB. Beta-amyloid efflux mediated by p-glycoprotein. J Neurochem 2001; 76: 1121-1128.
88. Larson EB, Wang L. Research and practice in Alzheimer's disease. Vol. 12. Serdi Publisher, Paris 2007; pp. 38-41.
89. Lashuel HA, Hartley DM, Balakhaneh D, Aggarwal A, Teichberg S, Callaway DJ. New class of inhibitors of amyloid-beta fibril formation. Implications for the mechanism of pathogenesis in Alzheimer's disease. J Biol Chem 2002; 277: 42881-42890. (Pubitemid 35285665)
90. Lau LF, Schachter JB, Seymour PA, Sanner MA. Tau protein phosphorylation as a therapeutic target in Alzheimer's disease. Curr Top Med Chem 2002; 2: 395-415.
91. Lee BC, Mintun M, Buckner RL, Morris JC. Imaging of Alzheimer's disease. J. Neuroimaging 2003; 13: 199-214. (Pubitemid 36775939)
92. Leissring MA, Farris W, Chang AY, Walsh DM, Wu X, Sun X, Frosch MP, Selkoe DJ. Enhanced proteolysis of beta-amyloid in APP transgenic mice prevents plaque formation, secondary pathology, and premature death. Neuron 2003; 40: 1087-1093. (Pubitemid 38032786)
93. Lemere CA, Beierschmitt A, Iglesias M, Spooner ET, Bloom JK, Leverone JF, Zheng JB, Seabrook TJ, Louard D, Li D, Selkoe DJ, Palmour RM, Ervin FR. Alzheimer's disease Abeta vaccine reduces central nervous system Abeta levels in a non-human primate, the Caribbean vervet. Am J Pathol 2004; 165: 283-297. (Pubitemid 38821835)
94. Lemere CA, Maier M, Jiang L, Peng Y, Seabrook TJ. Amyloidbeta immunotherapy for the prevention and treatment of Alzheimer disease: Lessons from mice, monkeys, and humans. Rejuvenation Res 2006; 9: 77-84.
95. Li L, Sengupta A, Haque N, Grundke-Iqbal I, Iqbal K. Memantine inhibits and reverses the Alzheimer type abnormal hyperphosphorylation of tau and associated neurodegeneration. FEBS Lett 2004; 566: 261-269. (Pubitemid 38625969)
96. Lue LF, Kuo YM, Roher AE, Brachova L, Shen Y, Sue L, Beach T, Kurth JH, Rydel RE, Rogers J. Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am J Pathol 1999; 155: 853-862. (Pubitemid 29426831)
97. Lupo G, Anfuso CD, Assero G, Strosznajder RP, Walski M, Pluta R, Alberghina M. Amyloid beta (1-42) and its beta (25-35) fragment induce in vitro phosphatidylcholine hydrolysis in bovine retina capillary pericytes. Neurosci Lett 2001; 303: 185- 188. (Pubitemid 32373286)
98. Lyketsos CG, Steinberg M, Tschanz JT, Norton MC, Steffens DC, Breitner JC. Mental and behavioral disturbances in dementia: findings from the Cache Country Study on Memory in Aging. Am J Psychiatry 2000; 157: 708-714. (Pubitemid 30249648)
99. Marco S, Skaper SD. Amyloid beta-peptide 1-42 alters tight junction protein distribution and expression in brain microvessels endothelial cells. Neurosci. Lett 2006; 401: 219-224. (Pubitemid 44250979)
100. Marr RA, Rockenstein E, Mukherjee A, Kindy MS, Hersh LB, Gage FH, Verma IM, Masliah E. Neprilysin gene transfer reduces human amyloid pathology in transgenic mice. J Neurosci 2003; 23: 1992-1996. (Pubitemid 36368884)
101. Martin-Villalba A, Hahne M, Kleber S, Vogel J, Falk W, Schenkel J, Krammer PH. Therapeutic neutralization of CD95-ligand and TNF attenuates brain damage in stroke. Cell Death Differ 2001; 8: 679-686. (Pubitemid 32685165)
102. Matsuoka Y, Saito M, LaFrancois J, Saito M, Gaynor K, Olm V, Wangl L, Casey E, Lu Y, Shiratori C, Lemere C, Duff K. Novel therapeutic approach for the treatment of Alzheimer's disease by peripheral administration of agents with an affinity to β-amyloid. J Neurosci 2003; 23: 29-33. (Pubitemid 36050401)
103. McCarty MF. Toward prevention of Alzheimer's disease - Potential nutraceutical strategies for suppressing the production of amyloid beta peptides. Med Hypotheses 2006; 67: 682-697.
104. McLean CA, Cherny RA, Fraser FW, Fuller SJ, Smith MJ, Beyreuther K, Bush AI, Masters CL. Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann Neurol 1999; 46: 860.
105. Mizutani T, Sakata M, Enomoto M, Kasahara M, Yamada S.. Pathological heterogeneity of Alzheimer type dementia. In Alzheimer Disease: Biology, Diagnosis and Therapeutics. Iqbal K, Winbland B, Nishimura T, Takeda M, Wisniewski HM (eds.). John Wiley & Sons Ltd., Chichester 1997; pp. 247-255.
106. Moore AH, O'Banion MK. Neuroinflammation and anti-inflammatory therapy for Alzheimer's disease. Adv Drug Del Rev 2002; 54: 1627-1656. (Pubitemid 35350856)
107. Morihara T, Teter B, Yang F, Lim GP, Boudinot S, Boudinot FD, Frautschy SA, Cole GM. Ibuprofen suppresses interleukin-1beta induction of pro-amyloidogenic alpha1-antichymotrypsin to ameliorate beta-amyloid pathology in Alzheimer's models. Neuropsychopharmacology 2005; 30: 1111-1120. (Pubitemid 40720969)
108. Mruthinti S, Buccafusco JJ, Hill WD, Waller JL, Jackson TW, Zamrini EY, Schade RF. Autoimmunity in Alzheimer's disease: increased levels of circulating IgGs binding Abeta and RAGE peptides. Neurobiol Aging 2004; 25: 1023-1032. (Pubitemid 38798064)
109. Mudher A, Lovestone S. Alzheimer's disease-do tauists and baptists finally shake hands? Trends Neurosci 2002; 25: 22-26. (Pubitemid 34093781)
110. Nawashiro H, Matin D, Hallenbeck JM. Neuroprotective effects of TNF binding protein in focal cerebral ischemia. Brain Res 1997; 778: 265-271. (Pubitemid 28037406)
111. Naslund J, Haroutunian V, Mohs R, Davis KL, Davies P, Greengard P, Buxbaum JD. Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. JAMA 2000; 283: 1571-1577. (Pubitemid 30161512)
112. Nicoll JA, Wilkinson D, Holmes C, Steart P, Markham H, Weller RO. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat Med 2003; 9: 448-452. (Pubitemid 36460079)
113. Niedermeyer E. Consideration of the ischemic basis and therapy of Alzheimer disease. Clin EEG Neurosci 2007; 38: 55-56. (Pubitemid 46696869)
114. Ooboshi H, Ibayashi S, Takada J, Kumai Y, Iida M. Brain ischemia as a potential target of gene therapy. Exp Gerontol 2003; 38: 183-187. (Pubitemid 36110512)
115. Oddo S, Billings L, Kesslak JP, Cribbs DH, LaFerla FM. Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron 2004; 43: 321-332. (Pubitemid 39061125)
116. Ohkura T, Isse K, Akazawa K, Hamamoto M, Yaoi Y, Hagino N. Evaluation of estrogen treatment in female patients with dementia of the Alzheimer type. Endocr J 1994; 41: 361-371. (Pubitemid 24297493)
117. Orgogozo JM, Gilman S, Dartigues JF, Laurent B, Puel M, Kirby LC, Jouanny P, Dubois B, Eisner L, Flitman S, Michel BF, Boada M, Frank A, Hock C. Subacute meningoencephalitis in a subset of patients with Alzheimer's disease after Abeta42 immunization. Neurology 2003; 61: 46-54. (Pubitemid 36818745)
118. Pluta R. Influence of prostacyclin on early morphological changes in the rabbit brain after complete 20-min ischemia. J Neurol Sci 1985; 70: 305-316. (Pubitemid 15242350)
119. Pluta R, Kida E, Lossinsky AS, Goła̧bek AA, Mossakowski MJ, Wisniewski HM. Complete cerebral ischemia with short-term survival in rats induced by cardiac arrest. I. Extracellular accumulation of Alzheimer's beta-amyloid protein precursor in the brain. Brain Res 1994; 649: 323-328. (Pubitemid 24197229)
120. Pluta R, Barcikowska M, Januszewski S, Misicka A, Lipkowski AW. Evidence of blood-brain barrier permeability/leakage for circulating human Alzheimer's beta-amyloid-(1-42)-peptide. NeuroReport 1996; 7: 1261-1265. (Pubitemid 26231596)
121. Pluta R, Misicka A, Januszewski S, Barcikowska M, Lipkowski AW. Transport of human beta-amyloid peptide through the rat blood-brain barrier after global cerebral ischemia. Acta Neurochir (Suppl.) 1997; 70: 247-249. (Pubitemid 127502109)
122. Pluta R. Experimental model of neuropathological changes characteristic for Alzheimer's disease. Folia Neuropathol 1997; 35: 94-98. (Pubitemid 127535389)
123. Pluta R, Barcikowska M, Misicka A, Januszewski S, Lipkowski AW. Disappearing diffuse amyloid plaques. Neurobiol Aging 1998; 19: S131.
124. Pluta R, Barcikowska M, Misicka A, Lipkowski AW, Spisacka S, Januszewski S. Ischemic rats as a model in the study of the neurobiological role of human β-amyloid peptide. Time-dependent disappearing diffuse amyloid plaques in brain. NeuroReport 1999; 10: 3615-3619.
125. Pluta R. The role of apolipoprotein E in the deposition of betaamyloid peptide during ischemia-reperfusion brain injury. A model of early Alzheimer's disease. Ann NY Acad Sci 2000; 903: 324-334. (Pubitemid 30251573)
126. Pluta R, Misicka A, Barcikowska M, Spisacka S, Lipkowski AW, Januszewski S. Possible reverse transport of beta-amyloid peptide across the blood-brain barrier. Acta Neurochir (Suppl) 2000; 76: 73-77.
127. Pluta R. Blood-brain barrier dysfunction and amyloid precursor protein accumulation in microvascular compartment following ischemia-reperfusion brain injury with 1-year survival. Acta Neurochir (Suppl) 2003; 86: 117-122.
128. Pluta R. Alzheimer lesions after ischemia-reperfusion brain injury. Folia Neuropathol 2004; 42: 181-186. (Pubitemid 39433405)
129. Pluta R. From brain ischemia-reperfusion injury to possible sporadic Alzheimer's disease. Curr Neurovasc Res 2004; 1: 441-453.
130. Pluta R. Pathological opening of the blood-brain barrier to horseradish peroxidase and amyloid precursor protein following ischemia-reperfusion brain injury. Chemotherapy 2005; 51: 223-226. (Pubitemid 41404703)
131. Pluta R, Ułamek M, Januszewski S. Micro-blood-brain barrier openings and cytotoxic fragments of amyloid precursor protein accumulation in white matter after ischemic brain injury in long-lived rats. Acta Neurochir (Suppl) 2006; 96: 267-271.
132. Pluta R. Ischemia-reperfusion factors in sporadic Alzheimer's disease. In: New Research on Alzheimer's disease. Welsh EM (ed.). Nova Science Publishers, New York 2006; pp.183-234.
133. Pluta R. Is the ischemic blood-brain barrier insufficiency responsible for full-blown Alzheimer's disease? Neurol Res 2006; 28: 266-271. (Pubitemid 44433327)
134. Pluta R, Ułamek M. Brain amyloidosis following ischemiareperfusion injury. Curr Trends Neurol 2006; 2: 41-46.
135. Pluta R. Role of ischemic blood-brain barrier on amyloid plaques development in Alzheimer's disease brain. Curr Neurovasc Res 2007; 4: 121-129. (Pubitemid 46708902)
136. Pluta R. Is the ischemic blood-brain barrier a Trojan horse in Alzheimer's disease brain? In: Ischemia-reperfusion pathways in Alzheimer's disease. Pluta R (ed.). Nova Science Publishers, Inc., New York 2007; pp.139-184. (Pubitemid 46708902)
137. Pluta R. Ischemia-reperfusion pathways in Alzheimer's disease. Nova Science Publishers, Inc., New York 2007.
138. Pluta R, Ułamek M. New proposals for treatment sporadic
139. Pluta R, Januszewski S, Ułamek M. Ischemic blood-brain barrier and amyloid in white matter as etiological factors in leukoaraiosis. Acta Neurochir Suppl 2008; 102: 353-356.
140. Pluta R, Ułamek M. Brain ischemia and ischemic blood-brain barrier as etiological factors in sporadic Alzheimer's disease. Neuropsychiatr Dis Treat 2008; 4: 855-864.
141. Pluta R, Ułamek M, Jabłoński M. Alzheimer's mechanisms in ischemic brain degeneration. Anat Rec 2009; 292: 1863-1881.
142. Pluta R, Januszewski S, Jabłoński M, Ułamek M. Factors in creepy delayed neuronal death in hippocampus following brain ischemia-reperfusion injury with long-term survival. Acta Neurochir Suppl 2010; 106: 37-41.
143. Pogue AI, Lukiw WJ. Angiogenic signaling in Alzheimer's disease. NeuroReport 2004; 15: 1507-1510.
144. Price DL, Sisodia SS. Mutant genes in familial Alzheimer's disease and transgenic models. Annu Rev Neurosci 1998; 21: 479- 505. (Pubitemid 28150671)
145. Rakover I, Arbel M, Solomon B. Immunotherapy against APP β-secretase cleavage site improves cognitive function and reduces neuroinflammation in Tg2576 mice without a significant effect on brain Aβ levels. Neurodegener Dis 2007; 4: 392- 402. (Pubitemid 47123466)
146. Ramirez BG, Blazquez C, Gomez del Pulgar T, Guzmain M, de Ceballos ML. Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation. J Neurosci 2005; 25: 1904-1913. (Pubitemid 40289395)
147. Rangan SK, Liu R, Brune D, Planque S, Paul S, Sierks MR. Degradation of beta-amyloid by proteolytic antibody light chains. Biochemistry 2003; 42: 14328-14334. (Pubitemid 37499430)
148. Reisberg B, Doody R, Stoffler A, Schmitt F, Ferris S, Mobius HJ, and Memantine Study Group. Memantine in moderate-tosevere Alzheimer's disease. N Engl J Med 2003; 348: 1333-1341.
149. Roberts SB. Gamma-secretase inhibitors and Alzheimer's disease. Adv Drug Deliv Rev 2002; 54: 1579-1588.
150. Rosenblum WI, Murata S, Nelson GH, Werner PK, Ranken R, Harmon RC. Anti-CD31 delays platelet adhesion/aggregation at sites of endothelial injury in mouse cerebral arterioles. Am J Pathol 1994; 145: 33-36. (Pubitemid 24217479)
151. Saito K, Suyama K, Nishida K, Sei Y, Basile AS. Early increases in TNF-alpha, IL-6 and IL-1 beta levels following transient cerebral ischemia in gerbil brain. Neurosci Lett 1996; 206: 149-152. (Pubitemid 26094682)
152. Sastre M, Dewachter I, Rossner S, Bogdanovic N, Rosen E, Borghgraef P, Evert BO, Dumitrescu-Ozimek L, Thal DR, Landreth G, Walter J, Klockgether T, Van Leuven F, Heneka MT. Nonsteroidal anti-inflammatory drugs repress beta-secretase gene promotor activity by the activation of PPARgamma. Proc Natl Acad Sci USA 2006; 103: 443-448. (Pubitemid 43122420)
153. Saver JL. Time is brain - quantified. Stroke 2006; 37: 263-266.
154. Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Liao Z, Lieberburg I, Motter R, Mutter L, Soriano F, Shopp G, Vasquez N, Vandevert C, Walker S, Wogulis M, Yednock T, Games D, Seubert P. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999; 400: 173-177. (Pubitemid 29327547)
155. Schmitt FA, Davis DG, Wekstein DR, Smith CD, Ashford JW, Markesbery WR. "Preclinical" Alzheimer's disease revisited: neuropathology of cognitively normal older adults. Neurology 2000; 55: 370-376.
156. Schott JM, Price SL, Frost C, Whitwell JL, Rossor MN, Fox NC. Measuring atrophy in Alzheimer disease - a serial MRI study over 6 and 12 months. Neurology 2005; 65: 119-124. (Pubitemid 40967786)
157. Schumock GT. Economic considerations in the treatment and management of Alzheimer's disease. Am J Health Syst Pharm 1998; 55 Suppl 2: S17-S21. (Pubitemid 28510078)
158. Selkoe DJ. Clearing the brain's amyloid cobwebs. Neuron 2001; 32: 177-180.
159. Selkoe DJ. Alzheimer's disease results from the cerebral accumulation and cytotoxicity of amyloid beta-protein. J Alzheimers Dis 2001; 3: 75-80.
160. Seubert P, Vigo-Pelfrey C, Esch F, Lee M, Dovey H, Davis D, Sinhas S, Schlossmacher M, Swindlehurst C, McCormack R, Wolfertt R, Selkoe D, Liberburg I, Schenk D. Isolation and quantification of soluble Alzheimer's beta-peptide from biological fluids. Nature 1992; 359: 325-327.
161. Snowdon DA, Greiner LH, Mortimer JA, Riley KP, Greiner PA, Markesbery WR. Brain infarction and the clinical expression of Alzheimer disease. The Nun Study JAMA 1997; 277: 813-817. (Pubitemid 27111317)
162. Snowdon DA. Healthy aging and dementia: findings from the nun study. Ann Int Med 2003; 139: 450-454., .
163. Sohrabji F. Guarding the blood-brain barrier: A role for estrogen in the etiology of neurodegenerative disease. Gene Expression 2007; 13: 311-319. (Pubitemid 47289404)
164. Soto C. Protein misfolding and disease; protein refolding and therapy. FEBS Lett 2001; 498: 204-207. (Pubitemid 32539204)
165. Spencer B, Rockenstein E, Crews L, Marr R, Masliah E. Novel strategies for Alzheimer's disease treatment. Expert Opin Biol Ther 2007; 7: 1853-1867. (Pubitemid 350247488)
166. Spires TL, Hyman BT. Transgenic models of Alzheimer's disease: learning from animals. NeuroRx 2005; 2: 423-437. (Pubitemid 41444876)
167. Spisacka S, Pluta R. Demographic and epidemiological profile of patients with Alzheimer's disease. Ann Univ M Curie- Skłodowska (Suppl. XIII) 2003; LVIII: 157-162.
168. Swerdlow RH, Khan SM. A "mitochondria cascade hypothesis" for sporadic Alzheimer's disease. Med Hypotheses 2004; 63: 8-20. (Pubitemid 38887104)
169. Swerdlow RH. Is aging part of Alzheimer's disease, or is Alzheimer's disease part of aging. Neurobiol Aging 2007; 28: 1465-1480.
170. Szekely CA, Thome JE, Zandi PP, Messias E, Breitner JC, Goodman SN. Nonsteroidal anti-inflammatory drugs for the prevention of Alzheimer's disease: a systematic review. Neuroepidemiology 2004; 23: 159-169. (Pubitemid 38980441)
171. Takada J, Ooboshi H, Ago T, Kitazono T, Yao H, Kadomatsu K, Muramatsu T, Ibayashi S, Iida M. Postischemic gene transfer of midkine, a neurotrophic factor, protects against focal brain ischemia. Gene Ther 2005; 12: 487-493. (Pubitemid 40439548)
172. Tanzi RE, Moir RD, Wagner SL. Clearance of Alzheimer's Abeta peptide: the many roads to perdition. Neuron 2004; 43: 605-608.
173. Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I, and Memantine Study Group. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trail. JAMA 2004; 291: 317-324. (Pubitemid 38101604)
174. Tarkowski E, Issa R, Sjogren M, Wallin B, Blennow K, Tarkowski A, Kumar P. Increased intrathecal levels of the angiogenic factors VEGF and TGF-beta in Alzheimer's disease and vascular dementia. Neurobiol Aging 2002; 23: 237-243. (Pubitemid 34137098)
175. Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R, Hansen LA, Katzman R. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol 1991; 30: 572-580.
176. Thomas T, Thomas G, McLendon C, Sutton T, Mullan M. beta- Amyloid-mediated vasoactivity and vascular endothelial damage. Nature 1996; 380: 168-171. (Pubitemid 26085884)
177. Vermeer SE, Prins ND, den Heijer T, Hofman A, Koudstaal PJ, Breteler MMB. Silent brain infarcts and the risk of dementia and cognitive decline. N Engl J Med 2003; 348: 1215-1222. (Pubitemid 36359297)
178. Vukovic V, Lovrencic-Huzjan A, Solter VV, Dordevic V, Demarin V. Hormone replacement therapy - is there a place for its use in neurology? Coll Antropol 2003; 27: 413-424. (Pubitemid 38376557)
179. Waring SC, Rocca WA, Petersen RC, O'Brien PC, Tangalos EG, Kokmen E. Postmenopausal estrogen replacement therapy and risk of AD: a population-based study. Neurology 1999; 52: 965- 970. (Pubitemid 29161604)
180. Wen Y, Yang SH, Liu R, Perez EJ, Brun-Ziukemagel AM, Koulen P, Simpkins JW. Cdk5 is involved in NFT-like tauopathy induced by transient cerebral ischemia in female rats. Biochim Biophys Acta 2007; 1772: 473-483. (Pubitemid 46400382)
181. Willing AE, Cuevas J, Pennypacker KR. Treatment of Alzheimer's disease: New insights from treatment of stroke at delayed time points. In: Ischemia-reperfusion pathways in Alzheimer's disease. Pluta R (ed.). Nova Science Publishers, Inc., New York 2007; pp. 185-203.
182. Wiśniewski HM, Maslińka D. Beta-protein immunoreactivity in the human brain after cardiac arrest. Folia Neuropathol 1996; 34: 65-71. (Pubitemid 126504537)
183. Xia CF, Yin H, Borlongan CV, Chao L, Chao J. Kallikrein gene transfer protects against ischemic stroke by promoting glial cell migration and inhibiting apoptosis. Hypertension 2004; 43: 452-459. (Pubitemid 38174153)
184. Xie CW. Calcium-regulated signaling pathways: role in amyloid beta-induced synaptic dysfunction. Neuromolec Med 2004; 6: 53-64.
185. Xuereb JH, Brayne C, Dufouil C, Gertz H, Wischik C, Harrington C, Mukaetova-Ladinska E, Mc Gee MA, O'Sullivan A, O'Connor D, Paykel ES, Huppert FA. Neuropathological findings in the very old. Results from the first 101 brains of a population-based longitudinal study of dementing disorders. Ann NY Acad Sci 2000; 903: 490-496. (Pubitemid 30251594)
186. Yang F, Lim GP, Begum AN, Ubeda OJ, Simmons MR, Ambegaokar SS, Chen PP, Kayed R, Glabe CG, Frautschy SA, Cole GM. Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J Biol Chem 2005; 280: 5892-5901. (Pubitemid 40280072)
187. Yang SH, Simpkins JW. Ischemia-reperfusion promotes tau and beta-amyloid pathology and a progressive cognitive impairment. In: Ischemia-reperfusion pathways in Alzheimer's disease. Pluta R (ed.). Nova Science Publishers, Inc., New York 2007; pp.113-138.
188. Youdim MB, Buccafusco JJ. Multi-functional drugs for various CNS targets in the treatment of neurodegenerative disorders. Trends Pharmacol Sci 2005; 26: 27-35. (Pubitemid 40052707)
189. Zhang RL, Chopp M, Liu Y, Zaloga C, Jiang N, Jones ML, Miyasaka M, Ward PA. Anti-ICAM-1 antibody reduces ischemic cell damage after transient middle cerebral artery occlusion in the rat. Neurology 1994; 44: 1747-1751. (Pubitemid 24286659)
190. Zhao H, Yenari MA, Cheng D, Barreto-Chang OL, Sapolsky RM, Steinberg GK. Bcl-2 transfection via herpes simplex virus blocks apoptosis-inducing factor translocation after focal ischemia in the rat. J Cereb Blood Flow Metab 2004; 24: 681-692. (Pubitemid 38725373)
191. Zipser BD, Johanson CE, Gonzalez L, Berzin TM, Tavares R, Hultte CM, Vitek MP, Hovanesian V, Stopa EG. Microvascular injury and blood-brain barrier leakage in Alzheimer's disease. Neurobiol Aging 2007; 27: 977-986. (Pubitemid 46635913)
192. Zlokovic BV, Martel CL, Matsubara E, McComb JG, Zhang G, McCluskey RT, Frangione B, Ghiso J. Glycoprotein 330/megalin: probable role in receptor-mediated transport of apolipoprotein J alone and in a complex with Alzheimer disease amyloid beta at the blood-brain and blood-cerebrospinal fluid barriers. Proc Natl Acad Sci USA 1996; 93: 4229-4234. (Pubitemid 26144268)
193. Zlokovic BV. Neurovascular mechanisms of Alzheimer's neurodegeneration. Trends Neurosci 2005; 28: 202-208.